Adding Antiplatelet During Edoxaban Treatment in Stroke Patients With Non-valvular Atrial Fibrillation (ADD-ON)

  • End date
    Feb 28, 2024
  • participants needed
  • sponsor
    Asan Medical Center
Updated on 23 January 2021


This study aims to compare the effectiveness and safety regarding treatment with standard anticoagulant only or adding antiplatelet to anticoagulant in patients with non-valvular atrial fibrillation and significant atherosclerosis including extracranial, intracranial, coronary or peripheral artery.


Although there is a significant increase in the risk of cerebral infarction in the presence of atrial fibrillation, it is difficult to say that all cerebral infarctions occurring in patients with atrial fibrillation are caused by atrial fibrillation. Carotid stenosis is found in 1/4 of patients with atrial fibrillation, which increases the risk of cerebral infarction. Additional antiplatelet therapy to standard anticoagulation therapy should be considered in some patients. To date, the best medical treatment for prevention of cerebral infarction in patients with atrial fibrillation and accompanying atherosclerosis has not been evaluated yet.

Edoxaban reduced bleeding complication compared to warfarin in patients with atrial fibrillation. In addition, the ENGAGE AF TIMI-48 study showed a tendency to reduce cerebral infarction (p for interaction = 0.08) when administered in combination with one antiplatelet agent and edoxaban. The administration of antiplatelet agents may be due to patients had accompanying myocardial infarction or cerebral infarction. This group is also thought to have a high risk of bleeding due to high HAS-BLED scores. Nonetheless, there was a similar degree of bleeding in patients receiving additional antiplatelet agents. There was also less bleeding in the warfarin arm than in the use of additional antiplatelet agents. (Major bleeding: 0.19 vs 0.24% / yr; intracranial hemorrhage: 0.43 vs 0.57% / yr)

Thus, Edoxaban have good clinical trial results in combination with antiplatelet agents in atrial fibrillation with atherosclerosis compared to other NOACs(new oral anticoagulants). It is also considered to be suitable for combination therapy with antiplatelet agents because of its advantages in different bleeding compared to other warfarin. However, there is no evidence to suggest that Edoxaban alone or in combination with additional antiplatelet agents is better for stroke patients with atrial fibrillation and significant arteriosclerosis.

Condition Arrhythmia, Dysrhythmia, Arrhythmia, Coronary Artery Disease, Coronary Artery Disease, Coronary heart disease, Atrial Fibrillation, Atrial Fibrillation, Atrial Fibrillation (Pediatric), Anticoagulants, Cerebral Atherosclerosis, Acute Ischemic Stroke, Atrial Fibrillation (Pediatric), Antiplatelet, Cardiac Ischemia, Dysrhythmia, Myocardial Ischemia, peripheral artery stenosis, anticoagulant, blood thinner, agents, anticoagulant, anticoagulation agents, blood thinners, anticoagulant drugs, intracranial atherosclerosis, anti-coagulant, Extracranial Atherosclerosis
Treatment Edoxaban Monotherapy
Clinical Study IdentifierNCT04010955
SponsorAsan Medical Center
Last Modified on23 January 2021


Yes No Not Sure

Inclusion Criteria

Patients with acute cerebral infarction or transient ischemic attack within 14 days of symptom onset based on Last Known Normal Time
Patients with non-valvular atrial fibrillation including paroxysmal atrial fibrillation which is eligible for treatment with Edoxaban
Patients with significant atherosclerosis confirmed by imaging tests on the cerebral arteries, coronary arteries, or peripheral arteries and suitable for the use of antiplatelet agents
Significant intracranial internal stenosis confirmed by CTA or MRA
A history of coronary artery disease, meaningful findings from CTA or CAG Arterial stenosis
Peripheral arterial disease (Ankle-Brachial Index, ABI <0.9, significant stenosis found in lower limb ultrasonography 3) Men and women over 20 years old 4) Patients who voluntarily agreed to register the registry

Exclusion Criteria

Patients with chronic renal failure (GFR <30 ml / min) or severe liver damage
patients requiring warfarin medication due to prosthetic valve replacement
patients with internal bleeding (active internal bleeding)
bleeding diathesis
History of acute myocardial infarction or received coronary artery procedure within 6 months before screening
Patients who have received or are scheduled to undergo carotid stenting within 1 year
Currently, two or more antiplatelet agents are required due to arteriosclerosis
Patients whose survival period is expected to be less than 12 months due to serious diseases such as terminal cancer or liver failure
Patients who are scheduled for invasive surgery with possible uncontrolled bleeding, including major surgery
Women who are pregnant or lactating, do not have contraception during the study
A person who is found to be unsuitable for participation in the study due to the clinical laboratory test results or other reasons
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note